Optimal Doses for Drug Provocation Tests to Beta-lactams
NCT ID: NCT02839551
Last Updated: 2025-09-30
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
NA
1252 participants
INTERVENTIONAL
2016-05-04
2021-11-16
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
investigators used 20 year experience in drug hypersensitivity to analyse retrospectively 171 patients (accounting for 182 positive DPT to beta-lactams). Using survival analysis, they identified optimal doses to include in a data-driven protocol. This data-driven protocol will be applied to new prospective patients, to test its safety and benefits (gain in time, hospital and patient benefits).
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Negative Predictive Value of Drug Provocation Tests to Beta-lactams
NCT02844712
Impact of Beta-lactams on the Microbiota and Relative Fecal Abundance of Mulltidrug Resistant Bacteria
NCT03338738
Beta-lactam Pharmacokinetics in Patients With Infective Endocarditis
NCT02033421
Prevalence of Enterobacteria With Decreased Susceptibility to Carbapenems in Eastern Inter- Region
NCT02803710
Study of the Impact of the Minimum Inhibitory Concentration and Susceptible Cut-off Points (CLSI, EUCAST, and Pharmacokinetics/Pharmacodynamics)in Prognosis of Bacteremia by Enterobacteriaceae
NCT02005159
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NA
SINGLE_GROUP
DIAGNOSTIC
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Simplified drug provocation test
Assessment of the Hypersensitivity to betalactams by simplified drug provocation test
simplified drug provocation test
Assessment of the Hypersensitivity to betalactams by simplified drug provocation test
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
simplified drug provocation test
Assessment of the Hypersensitivity to betalactams by simplified drug provocation test
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
* refusal of participation
* vulnerable patients according to French regulation
18 Years
65 Years
FEMALE
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
University Hospital, Montpellier
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
University hospital of Montpellier
Montpellier, France, France
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
RECHMPL15_0269
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.